Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Sisunatovir, RV521
PF-07923568 · 7 trials · 6 indications
Cmax was defined as maximum observed plasma concentration. Cmax was observed directly from data.
Cmax was defined as maximum observed plasma concentration.
Cmax was defined as maximum observed plasma concentration.
AUC12 was defined as area under the concentration-time curve from time zero to 12 hours.
AUC12 was defined as area under the concentration-time curve from time zero to 12 hours.
AUC12 was defined as area under the concentration-time curve from time zero to 12 hours.
AUClast was defined as area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.
AUCinf was defined as area under the concentration-time curve from time 0 to infinity.
Cmax was the highest concentration observed directly from data
AUClast was determined using linear/Log trapezoidal method
AUClast + (Clast\*/kel), where Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminalphase rate constant.
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were any AEs that occurred following start of treatment.
Laboratory tests included haematology (Monocytes \[10\^9/L\] increase: \> 1.2\* upper limit of normal \[ULN\] and Monocytes/Leukocytes \[percentage\] {%}:\> 1.2\* ULN); clinical chemistry (serum) included Alanine Aminotransferase (units per liter \[U/L\]):\> 3.0\* ULN and Bicarbonate (milliequivalents per liter) (mEq/L): \>1.1\* ULN and in urinalysis (urine Hemoglobin (Scalar) more than equal to (\>=) 1, urine Bilirubin (Scalar) \>= 1, Hyaline Casts (/Low power field \[LPF\]) \>= 1. Number of participants with any clinical laboratory abnormalities is reported in this outcome.
Supine blood pressure (BP) was measured with the participant's arm supported at the level of the heart and recorded after approximately 5 minutes of rest. Pulse rate was measured in the brachial/radial artery. Notable abnormal vital sign categories included: Systolic BP: \<90 millimeter of mercury \[mmHg\]; Systolic BP change from baseline: maximum increase and decrease \>=30 mmHg; Diastolic BP \<50 mmHg; Diastolic BP change from baseline: maximum decrease and increase ≥20 mmHg; pulse rate \<40 and \>120 beats per minute. Number of participants with newly occurring notable abnormal vital sign (i.e. change in supine systolic BP \>=30 millimeter of mercury \[mmHg\] increase) is reported in this outcome measure.
Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF), and QRS complex. ECG was performed after the participant had rested quietly for at least 5 minutes in a supine position. Clinical significance was determined by the investigator.
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
PK parameters of total radioactivity and RV521 following a single oral administration of \[ 14C\]-RV521 to healthy male subjects
Mass balance parameters in urinary and fecal excretion of radioactivity
Mass balance parameters in urinary and fecal excretion of radioactivity
Mass balance parameters in urinary and fecal excretion of radioactivity
Mass balance parameters in urinary and fecal excretion of radioactivity
Metabolite Profiling and Identification
Metabolite Profiling and Identification
| Arm | Type | Description |
|---|---|---|
| RV521 | EXPERIMENTAL | RV521 drug substance in capsule for oral administration |
| Placebo | PLACEBO_COMPARATOR | Micro-crystalline cellulose in capsule for oral administration |
| Arm 1 | EXPERIMENTAL | This only arm will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state |
| Cohort 1: Severe Renal Impairment | EXPERIMENTAL | Participants with severe renal impairment will receive a single oral dose of PF-07923568 |
| Cohort 2: Normal Renal Function | EXPERIMENTAL | Participants with normal renal function will receive a single oral dose of PF-07923568 |
| Cohort 3 (Optional): Moderate Renal Impairment | EXPERIMENTAL | Participants with moderate renal impairment will receive a single oral dose of PF-07923568 |
| Healthy subjects | EXPERIMENTAL | One time dose of 4 capsules taken orally. |
| Mild Hepatic impaired subjects | EXPERIMENTAL | One time dose of 4 capsules taken orally. |
| Moderate hepatic impaired subjects | EXPERIMENTAL | One time dose of 4 capsules taken orally |
| Severe Hepatic Impaired Subjects | EXPERIMENTAL | One time dose of 4 capsules taken orally. |
| Group A: Higher dose sisunatovir | EXPERIMENTAL | higher dose of sisunatovir dosed every 12 hours |
| Group B: Lower dose sisunatovir | EXPERIMENTAL | Lower dose of sisunatovir dosed every 12 hours |
| Group C: Placebo | PLACEBO_COMPARATOR | Placebo for sisunatovir dosed every 12 hours |
| Group D: Higher dose of sisunatovir | EXPERIMENTAL | Higher dose of sisunatovir dosed every 12 hours under fasted conditions |
| Group E: sisunatovir palatability | EXPERIMENTAL | Sisunatovir in 4 vehicles (water, saline, apple juice, infant formula) to assess the palatability of sisunatovir in each vehicle. sisunatovir will not be swallowed, participants will swirl and spit to assess various aspects of the taste. |
| 200 mg RV521/78 µCi [ 14C]-RV521 | EXPERIMENTAL | 200 mg RV521/78 µCi \[ 14C\]-RV521 |
| Name | Type | Description |
|---|---|---|
| RV521 | DRUG | RV521 drug in capsules |
| Placebo | DRUG | Placebo in capsules |
| Sisunatovir | DRUG | Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state |
| Drug: PF-07923568 | DRUG | A single dose of PF-07923568 administered orally as 4 capsules |
| PF-07923568 | DRUG | One time dose of 4 capsules taken orally. |
| 200 mg RV521/78 µCi [ 14C]-RV521. | DRUG | 200 mg RV521/78 µCi \[ 14C\]-RV521 |
Inclusion Criteria: * Age 18 to 45 years, inclusive * In good health with no history of major medical conditions * A total body weight ≥ 50 kg and a body mass index (BMI) of \>/=18kg/m2 and \</=30kg/m2 Exclusion Criteria: * Evidence of any clinically significant or currently active major medical ...
PF-07923568 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). It is being studied in Phase 1 clinical trials to understand how the body processes the medicine in people with liver or kidney impairment. It has not been approved for any indication.
PF-07923568 is not yet approved for any use. It is being evaluated in clinical trials for liver diseases and renal impairment. The studies are designed to assess how the drug is processed in participants with different levels of liver or kidney function.
PF-07923568 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical trials evaluating the drug in liver and kidney impairment.
PF-07923568 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no later-phase trials have been initiated. The drug remains investigational and has not been approved by the FDA or any regulatory authority.
PF-07923568 has been studied in two completed Phase 1 trials. NCT06037031 evaluated how the body processes the drug in people with loss of kidney function, enrolling 16 participants. NCT05857644 compared processing in participants with different levels of liver function loss to healthy participants, enrolling 28.
PF-07923568 is also referred to as Drug: PF-07923568 in clinical trial listings. No other alternative names are associated with this investigational compound.